



## Clinical trial results: Efficacy of Endothelin 1 receptor antagonist Bosentan in secondary Raynauds Syndrom Summary

EudraCT number	2004-002686-21
Trial protocol	AT
Global end of trial date	29 December 2009

### Results information

Result version number	v1 (current)
This version publication date	01 March 2022
First version publication date	01 March 2022

### Trial information

#### Trial identification

Sponsor protocol code	Bosentan1
-----------------------	-----------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Medical University
Sponsor organisation address	Anichstrasse 35, Innsbruck, Austria, 6020
Public contact	Wolfram Jaschke Consultant, Department of Dermatology, Venereology and Allergy Medical University Innsbruck, +43 51250483671, wolfram.jaschke@i-med.ac.at
Scientific contact	Wolfram Jaschke Consultant, Department of Dermatology, Venereology and Allergy Medical University Innsbruck, +43 51250483671, wolfram.jaschke@i-med.ac.at

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	29 December 2009
Is this the analysis of the primary completion data?	Yes
Primary completion date	29 December 2009
Global end of trial reached?	Yes
Global end of trial date	29 December 2009
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

Efficacy of bosentan in secondary raynauds syndrome.

Protection of trial subjects:

Patients were excluded if they had primary RP (Raynaud's phenomenon) or RP not associated with SSc (systemic sclerosis), active digital ulcer or gangrene, abnormal haemostasis, platelet alterations and evidence of uncontrolled cardiovascular, pulmonary, hepatic or renal disease. Other exclusion criteria were treatment with prostanoids within 3 months of enrolment, previous use of bosentan or other ET receptor blockers, phosphodiesterase-V-inhibitors and any medication contraindicating the administration of bosentan. Vasodilator drugs for arterial hypertension and the use of hand warmers or electric gloves were allowed, whereas topical treatment with glyceryl nitrate and therapy with paraffin wax hand baths were discontinued 4 weeks before starting the study. Women of child-bearing potential were required to have a negative pregnancy test before study initiation and apply effective contraceptive methods. All subjects were informed about the nature and aim of the study, and gave their informed written consent to participate.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	22 February 2005
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Austria: 17
Worldwide total number of subjects	17
EEA total number of subjects	17

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	14
From 65 to 84 years	3
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

The study was designed as a prospective, randomized, single-centre, observer-blinded, placebo-controlled trial and was conducted over the cold winter months to maximize the development of RP (Raynaud's phenomenon) as well as to minimize the seasonal effects on RP.

### Period 1

Period 1 title	Pre-treatment (2 weeks)
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	Selection
-----------	-----------

Arm description:

Randomization of trial participants

Arm type	Selection
----------	-----------

No investigational medicinal product assigned in this arm

Number of subjects in period 1	Selection
Started	17
Completed	17

### Period 2

Period 2 title	Treatment (16 weeks)
Is this the baseline period?	Yes <sup>[1]</sup>
Allocation method	Randomised - controlled
Blinding used	Single blind
Roles blinded	Subject

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Bosentan
Arm description: 62.5mg bosentan twice daily for 4 weeks, followed by 125mg twice daily for 12 weeks	
Arm type	Experimental
Investigational medicinal product name	Bosentan
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use
Dosage and administration details: 62.5mg bosentan twice daily for 4 weeks, followed by 125mg twice daily for 12 weeks	
<b>Arm title</b>	Placebo
Arm description: Placebo	
Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use
Dosage and administration details: 62.5mg placebo twice daily for 4 weeks, followed by 125mg twice daily for 12 weeks	
Notes: [1] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period. Justification: In the pre-treatment period subjects were randomized to one of the arms.	

Number of subjects in period 2	Bosentan	Placebo
Started	9	8
Completed	8	8
Not completed	1	0
Adverse event, non-fatal	1	-

<b>Period 3</b>	
Period 3 title	Post-treatment follow-up (8 weeks)
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded
<b>Arms</b>	
<b>Arm title</b>	Follow-up
Arm description: Follow-up visits were conducted for the trial participants.	
Arm type	Follow-up
No investigational medicinal product assigned in this arm	

<b>Number of subjects in period 3</b>	Follow-up
Started	16
Completed	16

## Baseline characteristics

### Reporting groups

Reporting group title	Bosentan
-----------------------	----------

Reporting group description:
------------------------------

62.5mg bosentan twice daily for 4 weeks, followed by 125mg twice daily for 12 weeks
---

Reporting group title	Placebo
-----------------------	---------

Reporting group description:
------------------------------

Placebo
---------

Reporting group values	Bosentan	Placebo	Total
Number of subjects	9	8	17
Age categorical			
Units: Subjects			
Adults (18-64 years)	9	8	17
From 65-84 years	0	0	0
Age continuous			
Units: years			
median	43	63.5	
standard deviation	± 11.2	± 9.9	-
Gender categorical			
Units: Subjects			
Female	9	8	17
Male	0	0	0

## End points

### End points reporting groups

Reporting group title	Selection
Reporting group description: Randomization of trial participants	
Reporting group title	Bosentan
Reporting group description: 62.5mg bosentan twice daily for 4 weeks, followed by 125mg twice daily for 12 weeks	
Reporting group title	Placebo
Reporting group description: Placebo	
Reporting group title	Follow-up
Reporting group description: Follow-up visits were conducted for the trial participants.	

### Primary: Primary Endpoint

End point title	Primary Endpoint <sup>[1]</sup>
End point description: The primary outcome was the change in severity of RP attacks, measured by the Raynaud condition score (RCS), and its related variables frequency, duration and pain at the end of the treatment period at Week 16 compared with the baseline.	
End point type	Primary
End point timeframe: Day 1 to Week 16	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Statistical analysis was done within groups.	

End point values	Bosentan	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8	8		
Units: RCS Score				
median (confidence interval 95%)	-36 (-75 to 4)	-31 (-66 to 4)		

### Statistical analyses

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Day 0 to week 16

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	CTCAE
-----------------	-------

Dictionary version	3.0
--------------------	-----

### Reporting groups

Reporting group title	Bosentan
-----------------------	----------

Reporting group description:

62.5mg bosentan twice daily for 4 weeks, followed by 125mg twice daily for 12 weeks

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Placebo

Serious adverse events	Bosentan	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Bosentan	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1 / 9 (11.11%)	0 / 8 (0.00%)	
Skin and subcutaneous tissue disorders			
treatment-related peripheral oedema			
subjects affected / exposed	1 / 9 (11.11%)	0 / 8 (0.00%)	
occurrences (all)	1	0	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/20040526>